Shots:
- Harbour BioMed & Otsuka Pharmaceutical have entered into a global strategic collaboration to advance HBM7020 for the treatment of autoimmune diseases
- As per the deal, Otsuka will receive an exclusive global license to develop, manufacture, & commercialize HBM7020 excl. Mainland China, Hong Kong, Macau & Taiwan in exchange for $47M in upfront & near-term payments as well as ~$623 in development & commercial milestones, with net sales-based tiered royalties
- HBM7020, developed using Harbour’s HBICE bispecific tech & Harbour Mice platform, is designed to bind BCMA & CD3 on cell surface, thereby, crosslinking T cells & target cells to trigger potent T cell activation & targeted cell killing
Ref: PRNewswire | Image: Harbour BioMed & Otsuka Pharmaceutical| Press Release
Related News:- Regeneron and Sanofi Receive the US FDA’s Approval for Dupixent to Treat Bullous Pemphigoid
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
